Banking on integrase inhibitors as HIV cornerstone, ViiV bags 3rd-generation compound from Shionogi

Amber Tong

As a 12% shareholder of ViiV Healthcare, Japan’s Shionogi has commanded a much lower profile than its fellow owners, GlaxoSmithKline and Pfizer. But behind the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Banking on integrase inhibitors as HIV cornerstone, ViiV bags 3rd-generation compound from Shionogi

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development

Bank­ing on in­te­grase in­hibitors as HIV cor­ner­stone, Vi­iV bags 3rd-gen­er­a­tion com­pound from Sh­iono­gi

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Banking on integrase inhibitors as HIV cornerstone, ViiV bags 3rd-generation compound from Shionogi